Misplaced Pages

This article provides insufficient context for those unfamiliar with the subject. Please help improve the article by providing more context for the reader. (March 2021) (Learn how and when to remove this message)

Azficel-T, sold under the brand name Laviv, is a cell therapy product for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. It consists of fibroblasts harvested from the patient's own skin.

It was approved for medical use in the United States in June 2011.

References

1. ^ "Laviv (Azficel-T)". U.S. Food and Drug Administration (FDA). 22 July 2017. Archived from the original on 16 December 2019. Retrieved 1 April 2020.
2. ^ "Autologous Fibroblasts". U.S. Food and Drug Administration (FDA). 29 June 2017. Archived from the original on 22 July 2017. Retrieved 1 April 2020.
3. "Laviv (azficel-T) Suspension for Intradermal Injection" (PDF). Food and Drug Administration. Archived from the original on 14 December 2019. Retrieved 2 April 2020.

Further reading

• Smith SR, Munavalli G, Weiss R, Maslowski JM, Hennegan KP, Novak JM (July 2012). "A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles". Dermatol Surg. 38 (7 Pt 2): 1234–43. doi:10.1111/j.1524-4725.2012.02349.x. PMID 22409385. S2CID 24901992.{{cite journal}}: CS1 maint: overridden setting (link)

External links

• "Laviv (azficel-T)". Medscape. 28 September 2019.
• Clinical trial number NCT02120781 for "Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia" at ClinicalTrials.gov

• Medicine

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Medical treatments
• Plastic surgery
• Pharmacology stubs
• Medical treatment stubs